Journal of Renal Nutrition
Volume 20, Issue 5 , Pages 293-302 , September 2010

Folic Acid Supplementation and Cardiac and Stroke Mortality among Hemodialysis Patients

  • June Leung, PhD, RD

      Affiliations

    • Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts
    • Corresponding Author InformationAddress reprint requests to June Leung, PhD, RD, Frances Stern Nutrition Center, Tufts Medical Center and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, 750 Washington St., Box 783, Boston, MA 02111.
    • ,
  • Brett Larive, MS

      Affiliations

    • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Johanna Dwyer, DSc, RD

      Affiliations

    • Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts
    • Department of Medicine and Community Health, Tufts University School of Medicine, Boston, Massachusetts
    • Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts
    • ,
  • Patricia Hibberd, MD, PhD

      Affiliations

    • Department of Public Health and Family Medicine, Tufts University School of Medicine, Boston, Massachusetts
    • Department of Medicine and Department of Pediatrics, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Paul Jacques, ScD

      Affiliations

    • Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts
    • Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts
    • ,
  • William Rand, PhD

      Affiliations

    • Department of Public Health and Family Medicine, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • HEMO Study Group

References 

  1. United States Renal Data System. USRDS 2002 annual data report. Bethesda, MD: United States Department of Health and Human Services, Public Health Service, National Institutes of Health; 2002;
  2. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?. Am J Kidney Dis. 1998;32:853–906
  3. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39(Suppl 2):S1–S246
  4. De Vecchi AF, Bamonti-Catena F, Finazzi S, et al. Homocysteine, vitamin B12, and serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients. Perit Dial Int. 2000;20:169–173
  5. Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000;57:1727–1735
  6. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol. 1997;17:2554–2558
  7. Friedman AN, Bostom AG, Selhub J, et al. The kidney and homocysteine metabolism. J Am Soc Nephrol. 2001;12:2181–2189
  8. Manns BJ, Burgess ED, Hyndman ME, et al. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end stage renal disease. Am J Kidney Dis. 1998;32:669–677
  9. Moustapha A, Gupta A, Robinson K, et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999;55:1470–1475
  10. Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis. 1995;114:93–103
  11. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–364
  12. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
  13. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart Study: A randomized controlled trial. JAMA. 2002;288:973–979
  14. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  15. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577
  16. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease. JAMA. 2008;299:2027–2036
  17. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography. JAMA. 2008;300:795–804
  18. Baker F, Picton D, Blackwood S. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: An outcome trial. Circulation. 2002;19:A3642
  19. Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA. 2006;296:2720–2726
  20. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet. 2007;369:1876–1882
  21. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet. 1998;351:263
  22. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Br Med J [Clin Res]. 1998;316:894–898
  23. Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51–60
  24. Ubbink JB, Vermaak WJ, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 1994;124:1927–1933
  25. Arnadottir M, Brattstrom L, Simonsen O, et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol. 1993;40:236–240
  26. Hyndman ME, Manns BJ, Snyder FF, et al. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: A link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease. Metabolism. 2003;52:168–172
  27. Ziakka S, Rammos G, Kountouris S, et al. The effect of vitamin B6 and folate supplements on plasma homocysteine and serum lipids levels in patients on regular hemodialysis. Int Urol Nephrol. 2001;33:559–562
  28. Trimarchi H, Schiel A, Freixas E, et al. Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients. Nephron. 2002;91:58–63
  29. Dierkes J, Domrose U, Bosselmann KP, et al. Homocysteine lowering effect of different multi-vitamin preparations in patients with end-stage renal disease. J Ren Nutr. 2001;11:67–72
  30. Stanford JL, Molina H, Phillips J, et al. Oral folate reduces plasma homocyst(e)ine levels in hemodialysis patients with cardiovascular disease. J Thorac Cardiovasc Surg. 2000;8:567–571
  31. Bostom AG, Shemin D, Bagley P, et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation. 2000;101:2829–2832
  32. Yango A, Shemin D, Hsu N, et al. Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int. 2001;59:324–327
  33. Arnadottir M, Gudnason V, Hultberg B. Treatment with different doses of folic acid in haemodialysis patients: Effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant. 2000;15:524–528
  34. Sunder-Plassmann G, Fodinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna Multicenter Study. J Am Soc Nephrol. 2000;11:1106–1116
  35. Gonin JM, Nguyen H, Gonin R, et al. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol. 2003;16:522–534
  36. Wrone EM, Hornberger JM, Zehnder JL, et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol. 2004;15:420–426
  37. Righetti M, Serbelloni P, Milani S, et al. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24:379–386
  38. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47:1108–1116
  39. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end stage renal disease. JAMA. 2007;298:1163–1170
  40. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  41. Makoff R. Water-soluble vitamin status in patients with renal disease treated with hemodialysis or peritoneal dialysis. J Ren Nutr. 1991;1:56–73
  42. Makoff R. Vitamin replacement therapy in renal failure patients. Miner Electrolyte Metab. 1999;25:349–351
  43. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004;65:2380–2389
  44. Miskulin DC, Athienites NV, Yan G, et al. Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney Int. 2001;60:1498–1510
  45. Stenvinkel P, Heimbürger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000;15:953–960
  46. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
  47. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  48. Bergstrom J, Heimbürger O, Lindholm B, et al. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J Am Soc Nephrol. 1995;6:573
  49. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658
  50. Ikizler TA, Wingard RL, Harvell J, et al. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int. 1999;55:1945–1951
  51. MacMahon M, Kirkpatrick C, Cummings CE, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis. 2000;10:195–203
  52. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13:120–126
  53. Galan P, de Bree A, Mennen L, et al. Background and rationale of the SU.FOL.OM3 Study: Double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging. 2003;7:428–435
  54. Bostom AG, Carpenter MA, Kusek JW, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am Heart J. 2006;152:448.e1–448.e7
  55. B Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials. Am Heart J. 2006;151:282–287

 This work was performed at the Frances Stern Nutrition Center, Tufts Medical Center, and Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts.

PII: S1051-2276(10)00006-3

doi: 10.1053/j.jrn.2010.01.005

Journal of Renal Nutrition
Volume 20, Issue 5 , Pages 293-302 , September 2010

Article Tools

* Image Usage & Resolution